Core Viewpoint - Algernon Health Inc. has successfully closed a non-brokered private placement financing, raising a total of CAD $858,000 to support its Alzheimer's Disease program and other operational expenses [2][4]. Financing Details - The total gross proceeds from the fourth tranche amounted to CAD $117,501 from the sale of 1,678,586 units at an issue price of CAD $0.07 per unit [2]. - The overall financing raised CAD $857,001 from the sale of 12,242,872 units across all tranches [2]. Insider Participation - Certain insiders participated in the fourth tranche, contributing CAD $32,501, which is classified as a "related party transaction" under MI 61-101 [3]. - The company is relying on exemptions from valuation and minority shareholder approval requirements as the insider purchases did not exceed 25% of the company's market capitalization [3]. Use of Proceeds - Proceeds from the offering will be allocated towards advancing the company's Alzheimer's Disease program, including the opening of its first U.S. clinic, as well as for general administrative expenses and working capital [4]. Company Overview - Algernon Health is focused on providing brain-optimized PET scanning services for early-stage detection of Alzheimer's Disease and other neurological conditions through a planned network of clinics in North America [7].

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, announces an increase to its non-brokered private placement financing, previously announced on November 6, 2025, to $750,000 and the closing of the third tranche (the “Third Tranche”). Gross proceeds from the Third Tranche totaled CA ...

Core Points - Algernon Health Inc. has closed the second tranche of its non-brokered private placement, raising gross proceeds of CAD $210,000 from the sale of 3,000,000 units at an issue price of CAD $0.07 per unit [2][3] - The funds raised will be utilized to advance the company's Alzheimer's Disease program, including the opening of its first U.S. Alzheimer's Disease clinic, as well as for general administrative expenses and working capital [3] - The securities issued are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with Canadian securities legislation [4] Company Overview - Algernon Health is a Canadian healthcare company focused on providing brain-optimized PET scanning services for early-stage detection of Alzheimer's Disease and other neurological conditions [6] - The company has established a private subsidiary, Algernon USA LLC, to oversee its U.S. neuroimaging operations [6]

Core Points - Algernon Health Inc. has closed the first tranche of its non-brokered private placement, raising gross proceeds of CAD $177,000 from the sale of 2,528,752 units at an issue price of CAD $0.07 per unit [2][4] - Insiders of the company participated in the first tranche, contributing CAD $37,000, which is classified as a related party transaction under MI 61-101 [3] - The proceeds from the first tranche will be allocated towards advancing the company's Alzheimer's Disease program, including the opening of its first U.S. AD clinic, as well as for general administrative expenses and working capital [4] Financial Details - The first tranche raised a total of CAD $177,000, with each unit priced at CAD $0.07 [2] - The participation of insiders did not exceed 25% of the company's market capitalization, allowing the company to rely on exemptions from certain requirements under MI 61-101 [3] Future Plans - Additional tranches of the offering are expected to close on or before December 1, 2025 [4] - The company is focused on establishing a network of clinics in North America for early-stage detection of Alzheimer's Disease and other neurological conditions [7]